Pfizer pharmaceuticals news
Pfizer unveiled its new R&D network after its acquisition of Wyeth. R&D will now be conducted at five main sites and nine specialized units, down from 20 main sites. The five main sites include: Cambridge, Mass.; Groton, Conn.; Pearl River, N.Y.; La Jolla, Calif.; and Sandwich, U.K. The units include mAb discovery in San Francisco, Calif.; regenerative medicine in Cambridge; U.K.; and R&D activities in Shanghai. Pfizer will discontinue R&D operations in Princeton, N.J.; Chazy, Rouses Point and Plattsburgh, N.Y.; Sanford and Research Triangle Park,N.C.; and Gosport and Slough/Taplow, U.K. The pharma also plans to consolidate R&D functions from its New London, Conn. site to Groton, and move some functions from Collegeville, Pa.; Pearl River, N.Y.; and St. Louis, Mo. to other locations. Pfizer expects the changes to result in undisclosed staff reductions. ...